Meloxicam Indications
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used primarily for chronic inflammatory conditions including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, with emerging evidence supporting its use for acute postoperative pain management. 1
Primary Indications
Chronic Inflammatory Conditions
Meloxicam is FDA-approved and guideline-supported for:
- Osteoarthritis - Most extensively studied indication 2
- Rheumatoid arthritis 1, 3
- Ankylosing spondylitis 1
- Juvenile idiopathic arthritis 1
The drug demonstrates efficacy comparable to traditional NSAIDs like piroxicam, diclofenac, and naproxen, with the advantage of once-daily dosing at 7.5-15 mg 3, 2.
Acute Pain Management
Intravenous meloxicam (30 mg once daily) is effective for moderate to severe postoperative pain, particularly following orthopedic, abdominal, and colorectal surgeries 4, 5. The IV formulation addresses the limitation of oral meloxicam's slow onset of action, making it suitable for acute perioperative use 4.
Dosing Strategy
Standard dosing is 7.5 mg once daily, with escalation to 15 mg daily if needed (maximum 7.5 mg in elderly patients) 1. The 3.75 mg dose lacks consistent efficacy and should be avoided 2. Rectal suppositories may be used at doses similar to oral administration 1.
Mechanism and Drug Classification
Meloxicam is a preferential COX-2 inhibitor (not a highly selective coxib), which positions it as a middle-ground option between nonselective NSAIDs and highly selective COX-2 inhibitors 1, 3, 6. This preferential selectivity is most pronounced at the lowest therapeutic dose (7.5 mg) 3.
Safety Profile Considerations
Gastrointestinal Safety
Meloxicam demonstrates gastrointestinal tolerability comparable to placebo at therapeutic doses, with lower rates of perforations, obstructions, and bleeding compared to traditional NSAIDs like diclofenac 3, 2. The incidence of GI adverse events and dropout rates due to GI issues match placebo levels 2.
Cardiovascular Considerations
As a moderately selective NSAID, meloxicam appears safer for cardiovascular use than highly selective COX-2 inhibitors (coxibs), while maintaining better GI tolerability than nonselective NSAIDs 6. It demonstrates good compatibility with low-dose aspirin 6, though standard NSAID precautions apply per guidelines 7.
Key Contraindications and Precautions
Based on NSAID class guidelines 7:
- Avoid in patients with history of NSAID-associated GI bleeding unless combined with PPI
- Use with extreme caution or avoid in patients with cardiovascular disease, heart failure, or hypertension
- Contraindicated in renal disease - NSAIDs impair renal function
- Avoid in cirrhosis due to hematologic and renal complications
- Do not combine with anticoagulants without gastroprotection (increases bleeding risk 3-6 fold)
- Avoid in late pregnancy (6-8 weeks before term)
- Use cautiously in asthma, especially with nasal polyps or recurrent sinusitis
Clinical Positioning
Meloxicam represents "the golden mean" among NSAIDs 6, offering a balance between efficacy, convenient once-daily dosing, and an acceptable safety profile for both GI and cardiovascular systems. This makes it particularly suitable for patients requiring chronic NSAID therapy who have moderate risk factors but cannot tolerate either highly selective COX-2 inhibitors (due to CV risk) or traditional NSAIDs (due to GI toxicity).